TP53 and KRAS co-mutations are associated with worse outcomes in mucinous ovarian carcinomas
A substantial proportion of mOCs have concurrent <i>TP53</i> and <i>KRAS</i> alterations on TMP, and this may portend worse survival, even for patients with early-stage disease. TMP could be a useful tool for prognostication and can be considered for patients with mOC at the time of diagnosis.
Authors
- Preetha Ramalingam (ORCID: https://orcid.org/0000-0002-4816-507X)
- Alejandra Flores Legarreta (ORCID: https://orcid.org/0000-0003-4533-2845)
- Panayiotis Kontoyiannis (ORCID: https://orcid.org/0000-0002-4850-4406)
- Yingao Zhang (ORCID: https://orcid.org/0000-0001-8589-8638)
- Michael Frumovitz (ORCID: https://orcid.org/0000-0002-0810-2648)
- Savannah Barkdull
- Anil K. Sood
- David M. Gershenson
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Baylor College of Medicine (US)
- The University of Texas Health Science Center (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-08-14
- DOI
- https://doi.org/10.3389/fonc.2025.1573801
- Citations
- 1
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.70